{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:04:05Z","timestamp":1773421445124,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s11938-007-0064-5","type":"journal-article","created":{"date-parts":[[2008,3,14]],"date-time":"2008-03-14T03:33:16Z","timestamp":1205465596000},"page":"123-133","source":"Crossref","is-referenced-by-count":40,"title":["Treatment of gastric carcinoids"],"prefix":"10.1007","volume":"10","author":[{"given":"Wei","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell L.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,15]]},"reference":[{"key":"64_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.sla.0000197734.28551.0f","volume":"243","author":"M. Kidd","year":"2006","unstructured":"Kidd M, Modlin IM, Mane SM, et al.: Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg 2006, 243:273\u2013280.","journal-title":"Ann Surg"},{"key":"64_CR2","first-page":"237","volume":"1","author":"S. Oberndorfer","year":"1907","unstructured":"Oberndorfer S: Karzinoide tumoren des dunndarms [in German]. Frankf Z Pathol 1907, 1:237\u2013240.","journal-title":"Frankf Z Pathol"},{"key":"64_CR3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4","volume":"36","author":"J.D. Godwin 2nd","year":"1975","unstructured":"Godwin JD 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975, 36:560\u2013569.","journal-title":"Cancer"},{"key":"64_CR4","first-page":"322","volume":"84","author":"T. Berge","year":"1976","unstructured":"Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand 1976, 84:322\u2013330.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"64_CR5","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00464-005-0232-4","volume":"19","author":"N. Hodgson","year":"2005","unstructured":"Hodgson N, Koniaris LG, Livingstone AS, Franceschi D: Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005, 19:1610\u20131612.","journal-title":"Surg Endosc"},{"key":"64_CR6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0306-3623(98)00221-3","volume":"32","author":"D. Chen","year":"1999","unstructured":"Chen D, Zhao CM, Lindstrom E, et al.: Rat stomach ECL cells up-date of biology and physiology. Gen Pharmacol 1999, 32:413\u2013422.","journal-title":"Gen Pharmacol"},{"key":"64_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00365528708991864","volume":"22","author":"J.M. Conlon","year":"1987","unstructured":"Conlon JM, Deacon CF, Richter G, et al.: Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987, 22:97\u2013105.","journal-title":"Scand J Gastroenterol"},{"key":"64_CR8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0950-3528(93)90035-Q","volume":"7","author":"E. Solcia","year":"1993","unstructured":"Solcia E, Rinidi G, Silini E, et al.: Enterochromaffin-like (ECL) cells and their growths: relationship to gastrin, reduced acid secretion and gastritis. Baillieres Clin Gastroenterol 1993, 7:149\u2013165.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"64_CR9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","volume":"104","author":"G. Rindi","year":"1993","unstructured":"Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993, 104:994\u20131006.","journal-title":"Gastroenterology"},{"key":"64_CR10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0016-5085(95)90376-3","volume":"109","author":"F.D. Manela","year":"1995","unstructured":"Manela FD, Ren J, Gao J, et al.: Calcitonin gene-related peptide modulates acid mediated somatostatin and gastrin release from rat antrum. Gastroenterology 1995, 109:701\u2013706.","journal-title":"Gastroenterology"},{"key":"64_CR11","first-page":"338","volume":"90","author":"C.J. Galligan","year":"1995","unstructured":"Galligan CJ, Lawton GP, Tang LH, et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995, 90:338\u2013352.","journal-title":"Am J Gastroenterol"},{"key":"64_CR12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000199786","volume":"41","author":"E. Solcia","year":"1998","unstructured":"Solcia E, Bordi C, Creutzfeld W, et al.: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1998, 41:185\u2013200.","journal-title":"Digestion"},{"key":"64_CR13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/1097-0142(19910201)67:3<663::AID-CNCR2820670323>3.0.CO;2-L","volume":"67","author":"C. Bordi","year":"1991","unstructured":"Bordi C, Yu JY, Baggi MT, et al.: Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991, 67:663\u2013672.","journal-title":"Cancer"},{"key":"64_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/00365528609003087","volume":"21","author":"K. Borch","year":"1986","unstructured":"Borch K, Renyall H, Liedberg G, et al.: Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986, 21:357\u2013363.","journal-title":"Scand J Gastroenterol"},{"key":"64_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0960-7404(03)00034-3","volume":"12","author":"I.M. Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M: Carcinoid tumor of the stomach. Surg Oncol 2003, 12:153\u2013172.","journal-title":"Surg Oncol"},{"key":"64_CR16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s002689900026","volume":"20","author":"G. Rindi","year":"1996","unstructured":"Rindi G, Bordi C, Rappel S, et al.: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996, 20:168\u2013172.","journal-title":"World J Surg"},{"key":"64_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archsurg.136.1.49","volume":"136","author":"M. Schindl","year":"2001","unstructured":"Schindl M, Kaserer K, Niederle B: Treatment of gastric neuroendocrine tumors-the necessity of a type-adapted treatment. Arch Surg 2001, 136:49\u201354.","journal-title":"Arch Surg"},{"key":"64_CR18","first-page":"280","volume":"16","author":"K.T. Moesta","year":"1990","unstructured":"Moesta KT, Schlag P: Proposal for a new carcinoid tumor staging system based on tumor tissue infiltration and primary metastasis: a prospective multicentre carcinoid tumor evaluation study. West German Surgical Oncologists\u2019 Group. Eur J Surg Oncol 1990, 16:280\u2013288.","journal-title":"Eur J Surg Oncol"},{"key":"64_CR19","first-page":"273","volume":"71","author":"C. Bordi","year":"1998","unstructured":"Bordi C, D\u2019Adda T, Azzoni C, Ferraro G: Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998, 71:273\u2013284.","journal-title":"Yale J Biol Med"},{"key":"64_CR20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2796.1998.00281.x","volume":"243","author":"R.T. Jensen","year":"1998","unstructured":"Jensen RT: Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998, 243:477\u2013488.","journal-title":"J Intern Med"},{"key":"64_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","volume":"240","author":"M.A. Maggard","year":"2004","unstructured":"Maggard MA, O\u2019Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 2004, 240:117\u2013122.","journal-title":"Ann Surg"},{"key":"64_CR22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0344-0338(11)80891-5","volume":"191","author":"C. Bordi","year":"1995","unstructured":"Bordi C: Endocrine tumors of the stomach. Pathol Res Pract 1995, 191:373\u2013380.","journal-title":"Pathol Res Pract"},{"key":"64_CR23","first-page":"2622","volume":"82","author":"F.R. Nobels","year":"1997","unstructured":"Nobels FR, Kwekkeboom DJ, Coopmans W, et al.: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622\u20132628.","journal-title":"J Clin Endocrinol Metab"},{"key":"64_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ajcp\/114.3.419","volume":"114","author":"C. Bordi","year":"2000","unstructured":"Bordi C, Azzoni C, Feraro G, et al.: Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol 2000, 114:419\u2013425.","journal-title":"Am J Clin Pathol"},{"key":"64_CR25","first-page":"26","volume":"17","author":"M. Giovannini","year":"1993","unstructured":"Giovannini M, Seitz JF, Thomas P, et al.: Endoscopic ultrasound examination using a curved-array transducer in benign and malignant diseases of the stomach. Results in 30 patients [in French]. Gastroenterol Clin Biol 1993, 17:26\u201332.","journal-title":"Gastroenterol Clin Biol"},{"key":"64_CR26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0167-0115(00)00217-2","volume":"97","author":"E. Lindstrom","year":"2001","unstructured":"Lindstrom E, Hakanson R: Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal. Regul Pept 2001, 97:169\u2013180.","journal-title":"Regul Pept"},{"key":"64_CR27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","volume":"128","author":"I.M. Modlin","year":"2005","unstructured":"Modlin IM, Kidd M, Latich I, et al.: Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717\u20131751.","journal-title":"Gastroenterology"},{"key":"64_CR28","first-page":"889","volume":"43","author":"R. Lebtahi","year":"2002","unstructured":"Lebtahi R, Le Cloirec J, Houzard C, et al.: Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002, 43:889\u2013895.","journal-title":"J Nucl Med"},{"key":"64_CR29","first-page":"1646","volume":"41","author":"F. Gibril","year":"2000","unstructured":"Gibril F, Reynolds JC, Lubensky IA, et al.: Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000, 41:1646\u20131656.","journal-title":"J Nucl Med"},{"key":"64_CR30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00006231-200208000-00006","volume":"23","author":"J.M. Zuetenhorst","year":"2002","unstructured":"Zuetenhorst JM, Hoefnageli CA, Boot H, et al.: Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002, 23:735\u2013741.","journal-title":"Nucl Med Commun"},{"key":"64_CR31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1572-0241.2003.04027.x","volume":"99","author":"I.M. Modlin","year":"2004","unstructured":"Modlin IM, Lye KD, Kidd M: A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004, 99:23\u201332.","journal-title":"Am J Gastroenterol"},{"key":"64_CR32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000201276","volume":"56","author":"S. Rappel","year":"1995","unstructured":"Rappel S, Altendorfhofmann A, Stolte M: Prognosis of gastric carcinoid tumors. Digestion 1995, 56:455\u2013462.","journal-title":"Digestion"},{"key":"64_CR33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.med.46.1.395","volume":"46","author":"J. Meko","year":"1995","unstructured":"Meko J, Norton J: Management of patients with Zollinger-Ellison syndrome. Ann Rev Med 1995, 46:395\u2013411.","journal-title":"Ann Rev Med"},{"key":"64_CR34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/11024150201680022","volume":"168","author":"I.M. Modlin","year":"2002","unstructured":"Modlin IM, Kidd M, Lye KD: Biology and management of gastric carcinoid tumors: a review. Eur J Surg 2002, 168:669\u2013683.","journal-title":"Eur J Surg"},{"key":"64_CR35","first-page":"338","volume":"90","author":"C.J. Galligan","year":"1995","unstructured":"Galligan CJ, Lawton GP, Tang LH, et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995, 90:338\u2013352.","journal-title":"Am J Gastroenterol"},{"key":"64_CR36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2003-37256","volume":"35","author":"J. Ichikawa","year":"2003","unstructured":"Ichikawa J, Tanabe S, Koizumi W, et al.: Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 2003, 35:203\u2013206.","journal-title":"Endoscopy"},{"key":"64_CR37","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0016-5085(92)90787-Y","volume":"102","author":"B.I. Hirschowitz","year":"1992","unstructured":"Hirschowitz BI, Griffith J, Pellegrin D, et al.: Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992, 102:1409\u20131418.","journal-title":"Gastroenterology"},{"key":"64_CR38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cgh.2005.12.008","volume":"4","author":"I.M. Modlin","year":"2006","unstructured":"Modlin IM, Latich I, Kidd M, et al.: Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006, 4:526\u2013547.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"64_CR39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","volume":"151","author":"S.V. Welin","year":"2004","unstructured":"Welin SV, Janson ET, Sundin A, et al.: High-dose treatment with a long acting somatostatin analogue in patients with disseminated mid-gut carcinoid tumors. Eur J Endocrinol 2004, 151:107\u2013112.","journal-title":"Eur J Endocrinol"},{"key":"64_CR40","first-page":"61","volume":"172","author":"R. Arnold","year":"1996","unstructured":"Arnold R, Trautmann ME, Creutzfeld W, et al.: Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996, 172:61\u201367.","journal-title":"Gut"},{"key":"64_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001813-199603000-00005","volume":"7","author":"L.Y. Dirix","year":"1996","unstructured":"Dirix LY, Vermeulen PB, Fierens H, et al.: Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors\u2014an antiangiogenic effect? Anticancer Drugs 1996, 7:175\u2013181.","journal-title":"Anticancer Drugs"},{"key":"64_CR42","first-page":"6977","volume":"48","author":"A. Schally","year":"1988","unstructured":"Schally A: Oncological applications of somatostatin analogue. Cancer Res 1988, 48:6977\u20136985.","journal-title":"Cancer Res"},{"key":"64_CR43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0029-1211980","volume":"106","author":"N. Hillman","year":"1998","unstructured":"Hillman N, Herranz L, Alverez C, et al.: Efficacy of octreotide in the regression of a metastatic carcinoid tumor despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 1998, 106:226\u2013230.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"64_CR44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"L.K. Kvols","year":"1986","unstructured":"Kvols LK, Moertel CG, O\u2019Connell MJ, et al.: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986, 315:663\u2013666.","journal-title":"N Engl J Med"},{"key":"64_CR45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0305-7372(94)90016-7","volume":"20","author":"K. Oberg","year":"1994","unstructured":"Oberg K: Treatment of neuroendocrine tumors. Cancer Treat Rev 1994, 20:331\u2013355.","journal-title":"Cancer Treat Rev"},{"issue":"Suppl1","key":"64_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000080743","volume":"80","author":"K. Oberg","year":"2004","unstructured":"Oberg K: Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 2004, 80(Suppl 1):57\u201361.","journal-title":"Neuroendocrinology"},{"key":"64_CR47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM197811092991908","volume":"299","author":"J.C. Frolich","year":"1978","unstructured":"Frolich JC, Bloomgarden ZT, Oates JA, et al.: The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978, 299:1055\u20131057.","journal-title":"N Engl J Med"},{"key":"64_CR48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-92-1-68","volume":"92","author":"K. Dharmsathaphorn","year":"1980","unstructured":"Dharmsathaphorn K, Sherwin RS, Cataland S, et al.: Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980, 92:68\u201369.","journal-title":"Ann Intern Med"},{"key":"64_CR49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","volume":"42","author":"I.I. Schnirer","year":"2003","unstructured":"Schnirer II, Yao JC, Ajani JA: Carcinoid\u2014a comprehensive review. Acta Oncol 2003, 42:672\u2013692.","journal-title":"Acta Oncol"},{"issue":"Suppl3","key":"64_CR50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000201206","volume":"55","author":"H. Ahlman","year":"1994","unstructured":"Ahlman H, Kolby L, Lundell, et al.: Clinical management of gastric carcinoid tumors. Digestion 1994, 55Suppl 3):77\u201385.","journal-title":"Digestion"},{"key":"64_CR51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0016-5085(98)70596-7","volume":"114","author":"A.D. Higam","year":"1998","unstructured":"Higam AD, Dimaline R, Varro A, et al.: Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998, 114:817\u2013822.","journal-title":"Gastroenterology"},{"key":"64_CR52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jso.20468","volume":"93","author":"G.F. Dakin","year":"2006","unstructured":"Dakin GF, Warner RR, Pomp A, et al.: Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006, 93:368\u2013372.","journal-title":"J Surg Oncol"},{"key":"64_CR53","first-page":"301","volume":"26","author":"A.M. Comaru-Schally","year":"2005","unstructured":"Comaru-Schally AM, Schally AV: A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int J Oncol 2005, 26:301\u2013309.","journal-title":"Int J Oncol"},{"key":"64_CR54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/eje.0.1510015","volume":"151","author":"G. Kaltsas","year":"2004","unstructured":"Kaltsas G, Rockall A, Papadogias D, et al.: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004, 151:15\u201327.","journal-title":"Eur J Endocrinol"},{"key":"64_CR55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1196\/annals.1294.026","volume":"1014","author":"E.P. Krenning","year":"2004","unstructured":"Krenning EP, Kwekkeboom DJ, Valkema R, et al.: Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004, 1014:234\u2013245.","journal-title":"Ann N Y Acad Sci"},{"issue":"8Suppl","key":"64_CR56","first-page":"14","volume":"26","author":"V. Boerlin","year":"2003","unstructured":"Boerlin V, van der Hoek J, Beglinger Ch, et al.: New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003, 26(8 Suppl):14\u201316.","journal-title":"J Endocrinol Invest"},{"key":"64_CR57","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C. Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, et al.: SOM230: a novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707\u2013716.","journal-title":"Eur J Endocrinol"},{"issue":"Suppl1","key":"64_CR58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"H.A. Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1):47\u201350.","journal-title":"Neuroendocrinology"},{"key":"64_CR59","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1200\/jco.2005.23.16_suppl.8024","volume":"23","author":"L. Kvols","year":"2005","unstructured":"Kvols L, Oberg K, de Herder W: Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR [abstract]. Proc Am Soc Clin Oncol 2005, 23:8024.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"64_CR60","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/jco.2004.22.14_suppl.3013","volume":"22","author":"J.C. Yao","year":"2004","unstructured":"Yao JC, Chamsangavej C, Faria SC: Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. ASCO annual meeting proceedings (post-meeting edition) [abstract]. J Clin Oncol 2004, 22:3013.","journal-title":"J Clin Oncol"},{"key":"64_CR61","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/jco.2004.22.14_suppl.4124","volume":"22","author":"K. Carr","year":"2004","unstructured":"Carr K, Yao JC, Rashid A: A phase II trial of imatinib in patients with advanced carcinoid tumor. ASCO annual meeting proceedings (post-meeting edition) [abstract]. J Clin Oncol 2004, 22:4124.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0064-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-007-0064-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0064-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:36Z","timestamp":1559436996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-007-0064-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1007\/s11938-007-0064-5","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}